Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib works well and is safe for treating alopecia areata.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This study suggests that the expression and localization of toll-like receptors and caveolin-1 in lichen planopilaris may influence cicatricial alopecia pathobiology and that downregulating caveolae could offer a novel management strategy.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

The LTF gene may help predict and manage nonspecific orbital inflammation.

In this review, platelet concentrates were found to show comparable efficacy to steroids and immunosuppressive drugs in treating oral lichen planus, with some studies reporting more benefits and others noting more severe adverse reactions with platelet treatments.

This article discusses the colocalization of alopecia areata and lichen planus in pediatric dermatology and does not present new clinical results.

This study suggested that differences in hair follicle development, indicated by the frequency of underdeveloped hairs, significantly contribute to the variation in hair loss severity among Japanese individuals with the LIPH c.736T>A mutation.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This article reports a rare case of a postmenopausal woman with coexisting lichen planus pigmentosus and classic lichen planopilaris, alongside a review of related literature.

This case report documents the rare occurrence of lipedematous scalp in two black Caribbean female siblings, suggesting a potential genetic factor and noting psychiatric co-morbidities as novel associations.

This systematic review found that low-level light/laser therapy showed a positive effect in treating male and female pattern hair loss without side effects, as reported by all analyzed randomized controlled trials.

This case report highlights a rare presentation of acute lupus hemophagocytic syndrome with initially negative antinuclear antibodies, underscoring the higher sensitivity of the 2012 Systemic Lupus International Collaborating Clinics criteria for diagnosis.

This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.

This report identified a family of Iranian siblings with diverse clinical forms of Lichen Planus, suggesting potential genetic and environmental involvement in its pathogenesis.

This study reports that the Luce LDS 100 infrared light therapy shows positive hair growth results after one year in men and women with androgenetic alopecia.

The review concluded that better studies are needed to prove if Low-Level Laser Therapy devices for hair growth really work.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study identified a novel mechanism by which dsRNA-induced TLR3 activation and retinoic acid pathways contribute to new hair follicle formation after deep wounds in mice and suggested a similar potential in humans.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study found that activation of RORA significantly promotes the level of autophagy in rat hair follicle stem cells, suggesting a potential target for research on hair follicle development and treatments for conditions like alopecia.

This case report details the occurrence of paroxysmal nocturnal haemoglobinuria in a 19-year-old woman with systemic lupus erythematosus to raise clinician awareness of this rare association.

This study discovered that a specific G to C mutation in the ornithine aminotransferase gene is linked to the retarded hair growth phenotype in mice and may serve as a model for human gyrate atrophy.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This case report describes a 36-year-old man who developed generalized eruptive histiocytosis on the scalp after undergoing nine platelet-rich plasma treatments for hair loss, likely triggered by injection-related trauma and inflammation.

This article discusses the classification of mental retardation based on IQ ranges and provides no new experimental findings.

This article describes the first reported case of isolated linear discoid lupus erythematosus on the scalp, suggesting it should be considered in the differential diagnosis of linear scarring alopecia.

The authors concluded that the combination of 755 nm alexandrite laser and topical licorice is more effective than the alexandrite laser alone in reducing idiopathic hirsutism in women, with no serious adverse reactions reported.

This article discusses various aspects of rhinophyma, including its pathogenesis, differential diagnosis, and treatment options, without presenting new clinical research results.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.